为您找到"
N1048
"相关结果约100,000,000个
N1048 is a surface mount ceiling or wall luminaire with a 10"×48" ADA compliant lens and a 45W LED lamp. It has a constant current driver, a motion sensor option, and a limited five-year warranty.
Patients with intermediate-risk rectal cancer who received neoadjuvant chemotherapy with selective use of pelvic chemoradiation therapy had disease-free survival that was noninferior to the standard approach using pelvic chemoradiation, according to findings from the randomized phase III PROSPECT trial (Alliance N1048), which were reported during the Plenary Session of the 2023 ASCO Annual ...
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted.
SWOG clinical trial number CTSU/N1048 A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Kenall® NOVA II™ N1048-C-2-32-IS-DV Fluorescent Ceiling Fixture, (2) F32T8 Linear Fluorescent Lamp, 120 to 270 VAC
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
N1048 NCCTG N1048 (PROSPECT**): A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
The Alliance trial, N1048, also referred to as PROSPECT (Preoperative Radiation Or Selective Preoperative radiation and Evaluation before Chemotherapy and TME), is a randomized phase II/III trial of the selective use of radiation therapy in intermediate risk clinical stage II-III rectal cancer.
N1048 Nova II for Institutional High Abuse ... SPEC SHEET IES Specifications are subject to change without notice. Please consult your Kenall Customer Service for help with special requests at (800) 4 Kenall.
[$] [Abbreviated - Closed] The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are ...